Compare ARK Genomic Revolution ETF (ARKG) vs VNET Group Inc (VNET) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs VNET Group Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while VNET Group Inc trades at $7.8 (market cap $2.28B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | VNET | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $14.03 |
52-Week Low | $23.09 | $7.34 |
Market Cap | — | $2.28B |
Enterprise Value | — | $5.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
VNET trades at $8.01, down 0.5% with bearish technical signals. The company reported Q1 2026 revenue growth driven by AI demand but posted a significant net loss of $1.20 per share, missing estimates. Analyst sentiment remains positive with 62.5% buy ratings and a 54% upside target. Recent strategic investments and leadership changes signal transformation amid ongoing profitability challenges.
The outlook balances strong AI-driven revenue potential against persistent profitability concerns. Investment opportunity lies in market share gains from AI infrastructure demand, while risks include negative margins, class action litigation, and execution challenges during leadership transition. The stock faces near-term pressure from consecutive earnings misses despite long-term growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
